Evidence map›Paper›PMID 37065467›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2022

Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant

Malvika Kaul, Edgar Ferrer-González, Lilly Mark, Ajit K Parhi, Edmond J LaVoie, Daniel S Pilch

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Antibiotic synergy againstAntimicrobial agents and chemotherapy · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Malvika KaulDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.
Edgar Ferrer-GonzálezDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.
Lilly MarkTAXIS Pharmaceuticals, Inc., 9 Deer Park Drive, Suite J-15, Monmouth Junction, NJ 08852, USA.
Ajit K ParhiTAXIS Pharmaceuticals, Inc., 9 Deer Park Drive, Suite J-15, Monmouth Junction, NJ 08852, USA.
Edmond J LaVoieDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
Daniel S PilchDepartment of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.ORCID 0000-0002-0113-0849
Rutgers, The State University of New Jersey · US

Funding

Development of New Antibiotics Against Multidrug-Resistant Staphylococcus aureusR01AI118874 · NIAID · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI PILCH, DANIEL S · 2016 to 2020
$2.0M
NIAID NIH HHS R01 AI118874
6 · The paper itself

Abstract

Oxacillin is a first-line antibiotic for the treatment of methicillin-sensitive

Indexed as

Bactericidal synergyCombination antibiotic treatment of MRSAFtsZ inhibitorMislocalization of staphylococcal PBP2Repurposing antibiotics

Identifiers

PMID37065467
PMCPMC10104549
OpenAlexW4294683130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.